Trial Profile
A multicenter, open-label, Phase 1b maximal use (MUse) pharmacokinetic study of SNA-120 for moderate to severe itch associated with moderate to severe psoriasis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Jul 2019
Price :
$35
*
At a glance
- Drugs Pegcantratinib (Primary)
- Indications Psoriasis
- Focus Adverse reactions; Pharmacokinetics
- 31 Jul 2018 New trial record
- 24 Jul 2018 Results presented in a Sienna Biopharmaceuticals media release.